title: Resveratrol Treatment Inhibits Proliferation of and Induces Apoptosis in Human Colon Cancer Cells.
abstract: BACKGROUND
  Resveratrol, a natural isolate from plant sources, has a long and important history in traditional Chinese medicine. In the present study we investigated the effect of resveratrol on human colon cancer cell lines.
  
  
  METHODS
  We used the Cell Counting kit-8 (CCK-8) for determination of colon cancer cell viability. Apoptosis induction was analyzed using the DeadEnd™ Colorimetric TUNEL System (Promega, Madison, WI, USA). The siRNA Transfection Reagent kit (Santa Cruz Biotechnology, Inc.) was used for the administration of COX-2 silencer RNA (siRNA) into the colon cancer cells. Primer Express® software for Real-Time PCR ver. 3.0 (Applied Biosystems, Foster City, CA, USA) was used to prepare the primers for RT-PCR.
  
  
  RESULTS
  The results revealed that exposure of colon cancer cells to resveratrol inhibited cell viability. Resveratrol exhibited a significant inhibitory effect on cell viability at 30 μM concentration after 48 h of exposure. We observed that 30-μM doses of resveratrol for 72 h led to 18, 29, and 34% reduction in the viability of HCA-17, SW480, and HT29 cells, respectively. It also significantly induced apoptosis in both of the tested carcinoma cell lines. The population of apoptotic cells in HCA-17 and SW480 cell lines after 48 h of resveratrol treatment was 59.8±4 and 67.2±4%, respectively, compared to 2.3±1% in the control cells. The colon cancer cells exposed to resveratrol showed significantly lower cyclooxygenase-2 and prostaglandin receptor expression. Treatment of colon cancer cells with the inhibitor of cyclooxygenase-2, indomethacin, and administration of silencer RNA for cyclooxygenase-2 also produced similar results.
  
  
  CONCLUSIONS
  These findings suggest that resveratrol treatment can be a promising strategy for the treatment of colon cancer.
authors.affiliation: Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China (mainland).
authors.forename: Miao
authors.initials: M
authors.lastname: Feng
authors.affiliation: Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China (mainland).
authors.forename: Lu-Xing
authors.initials: LX
authors.lastname: Zhong
authors.affiliation: Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China (mainland).
authors.forename: Zheng-Yu
authors.initials: ZY
authors.lastname: Zhan
authors.affiliation: Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China (mainland).
authors.forename: Zhi-Hao
authors.initials: ZH
authors.lastname: Huang
authors.affiliation: Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China (mainland).
authors.forename: Jian-Ping
authors.initials: JP
authors.lastname: Xiong
mesh_terms: D017209:Apoptosis / Q000187:drug effects*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D003110:Colonic Neoplasms / Q000473:pathology*; D051546:Cyclooxygenase 2 / Q000378:metabolism; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D015232:Dinoprostone / Q000378:metabolism; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology; D011982:Receptors, Prostaglandin / Q000378:metabolism; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology*
chemical_list: D016861:Cyclooxygenase Inhibitors; D011982:Receptors, Prostaglandin; D013267:Stilbenes; D051546:Cyclooxygenase 2; D015232:Dinoprostone; D000077185:Resveratrol; D007213:Indomethacin